Article Text

Download PDFPDF
In patients with type 2 diabetes, perindopril-indapamide had similar relative reductions in mortality and cardiac events regardless of AF status

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Study design


post hoc subgroup analysis of a randomised placebo-controlled trial (Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation [ADVANCE] study). NCT00145925.




blinded (patients and outcome adjudication committee).†

Study question


{215 centres in 20 countries in Asia, Australasia, Europe, and North America}.*


11 140 patients ⩾55 years of age (mean age 66 y, 57% men) who had type 2 diabetes and ⩾1 additional risk factor for cardiovascular events. 847 patients (7.6%) had atrial fibrillation (AF). Patients requiring long-term insulin were excluded.


fixed combination of perinodopril and indapamide (2 mg/0.625 mg for 3 mo, then 4 mg/1.25 mg) (n = 5569), or placebo (n = 5571).


all-cause mortality, cardiovascular (CV) mortality, major cardiac events, major cerebral events, and heart failure.

Follow-up period:

mean 4.3 years.

Patient follow-up:

94% (100% in intention-to-treat analysis).

Main results

At baseline, …

View Full Text


  • Source of funding: National Health and Medical Research Council of Australia and Servier, France.